Fluorine-18 (18F)-radiolabeled PSMA ligands benefit from the more favorable physical properties: the lower kinetic energy results in a higher spatial resolution, and the longer half-life (110 versus 68 min) allows for a better tumor to background ratio in delayed imaging when compared to 68 Ga. The gene discussed is FOLH1; the disease is neoplasm.